- Current Issue
Volume 73, Issue 3, 2024
- Clinical Microbiology
-
-
-
Novel automated antifungal susceptibility testing system for yeasts based on dual-detection algorithm of turbidimetry and colorimetry
Introduction. The increasing prevalence and growing resistance of fungi present a significant peril to public health. There are only four classes of antifungal medicines available today, and few candidates are in clinical trials.
Hypothesis/Gap Statement. Rapid and sensitive diagnostic techniques are lacking for most fungal pathogens, and those that do exist are expensive or hard to obtain.
Aim. This study aimed to evaluate the feasibility of a novel automated antifungal susceptibility testing system, Fungus AST, in comparison to the broth microdilution method (BMD) recommended by the Clinical and Laboratory Standards Institute (CLSI).
Methodology. A total of 101 clinical Candida spp. isolates were collected from the Zengcheng Branch of Nanfang Hospital and subjected to antifungal susceptibility testing. Antifungal susceptibility was assessed using the Fungus AST method and the BMD.
Results. In this study, we introduce a novel automated antifungal susceptibility testing system, Fungus AST, which detects the turbidity and/or colour intensity of microdilution wells using a four-wavelength detection technology in real time and is designed to match the growth characteristics of strains over time. Based on our analysis, all reportable ranges of Fungus AST were suitable for clinical fungal isolates in PR China. Within ±twofold dilutions, reproducibility was 100 %. Considering the BMD as a referenced method, ten antifungal agents (anidulafungin, caspofungin, micafungin, fluconazole, voriconazole, posaconazole, itraconazole, amphotericin B, 5-flucytosine and nystatin) showed an essential agreement of >95 %. The category agreement of five antifungal agents (anidulafungin, caspofungin, micafungin, fluconazole and voriconazole) was excellent at >90 %. One Candida albicans isolate and voriconazole showed a major error (ME) (1.7 %), and no other ME or very ME agents were found.
Conclusion. Given the above, it can be argued that the utilization of Fungus AST is a discretionary automated approach. More improvements are needed in Fungus AST compared to the BMD system for a wider range of clinical isolates, including different types of fungi.
-
-
Volumes and issues
-
Volume 73 (2024)
-
Volume 72 (2023 - 2024)
-
Volume 71 (2022)
-
Volume 70 (2021)
-
Volume 69 (2020)
-
Volume 68 (2019)
-
Volume 67 (2018)
-
Volume 66 (2017)
-
Volume 65 (2016)
-
Volume 64 (2015)
-
Volume 63 (2014)
-
Volume 62 (2013)
-
Volume 61 (2012)
-
Volume 60 (2011)
-
Volume 59 (2010)
-
Volume 58 (2009)
-
Volume 57 (2008)
-
Volume 56 (2007)
-
Volume 55 (2006)
-
Volume 54 (2005)
-
Volume 53 (2004)
-
Volume 52 (2003)
-
Volume 51 (2002)
-
Volume 50 (2001)
-
Volume 49 (2000)
-
Volume 48 (1999)
-
Volume 47 (1998)
-
Volume 46 (1997)
-
Volume 45 (1996)
-
Volume 44 (1996)
-
Volume 43 (1995)
-
Volume 42 (1995)
-
Volume 41 (1994)
-
Volume 40 (1994)
-
Volume 39 (1993)
-
Volume 38 (1993)
-
Volume 37 (1992)
-
Volume 36 (1992)
-
Volume 35 (1991)
-
Volume 34 (1991)
-
Volume 33 (1990)
-
Volume 32 (1990)
-
Volume 31 (1990)
-
Volume 30 (1989)
-
Volume 29 (1989)
-
Volume 28 (1989)
-
Volume 27 (1988)
-
Volume 26 (1988)
-
Volume 25 (1988)
-
Volume 24 (1987)
-
Volume 23 (1987)
-
Volume 22 (1986)
-
Volume 21 (1986)
-
Volume 20 (1985)
-
Volume 19 (1985)
-
Volume 18 (1984)
-
Volume 17 (1984)
-
Volume 16 (1983)
-
Volume 15 (1982)
-
Volume 14 (1981)
-
Volume 13 (1980)
-
Volume 12 (1979)
-
Volume 11 (1978)
-
Volume 10 (1977)
-
Volume 9 (1976)
-
Volume 8 (1975)
-
Volume 7 (1974)
-
Volume 6 (1973)
-
Volume 5 (1972)
-
Volume 4 (1971)
-
Volume 3 (1970)
-
Volume 2 (1969)
-
Volume 1 (1968)